# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `full27_study-forensics-032_Claude_Haiku_d66f0d`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:06:56.127529+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** missed_key_insight, unsupported_conclusion, wrong_answer
**Forensic flags:** 2
**Consistency findings:** 4
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 5.6/8 | 8.0/8 | 0.0/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [x] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** cautious_scope_control, none_or_minor, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: No match (got: mechanism_vs_evidence)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "MECHANISM VS. EVIDENCE CLASSIFICATION: The text implies human therapeutic benefit (cardiovascular protection, transforme"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[3]`: "The company's claims about 'cardiovascular protection' and 'transforming outcomes' are being made in the announcement te"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[3]`: "The baseline cardiovascular risk of the trial population and whether the 65% reduction is clinically meaningful in absol"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[1]`: "Could classify as 'solid' if one accepts that surrogate endpoints are sufficient for Phase 2 claims and that the company"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[1]`: "Did I correctly identify the conclusion tier? Yes—'cardiovascular protection' and 'transform outcomes for patients at hi"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.70, 640 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "se 2 trial. this is biomarker/surrogate endpoint evidence, not clinical outcom"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'overclaim'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'overclaim', detected 'mechanism_vs_evidence'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/14 content words)
  - `key_claims[0]`: "The core epistemic problem: LDL reduction (biomarker) is presented as evidence of cardiovascular pro"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/10 content words)
  - `key_claims[1]`: "Accelerated approval based on surrogate endpoints is a regulatory risk if the surrogate does not tra"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/11 content words)
  - `key_claims[2]`: "The 12-week timeframe is too short to assess safety signals that might emerge over years of use."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/11 content words)
  - `key_claims[3]`: "The company's language ('breakthrough,' 'transform outcomes') is not hedged despite the absence of c"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 14398ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.92

**Assumptions:**
- The Phase 2 trial is a legitimate randomized controlled trial with appropriate controls
- The 65% LDL reduction is accurately measured and statistically significant
- LDL cholesterol is a valid surrogate endpoint for cardiovascular risk
- The company's claims about 'cardiovascular protection' and 'transforming outcomes' are being made in the announcement text

**Reasoning Steps:**
1. EVIDENCE TIER IDENTIFICATION: The study measured biomarkers (LDL cholesterol levels) and safety over 12 weeks in a Phase 2 trial. This is biomarker/surrogate endpoint evidence, not clinical outcome evidence.
2. CONCLUSION TIER IDENTIFICATION: The company describes results as 'a major breakthrough in cardiovascular protection' and claims the drug will 'transform outcomes for patients at high risk of heart attack and stroke.' These are claims about clinical human therapeutic benefit (reduction in actual cardiovascular events).
3. BRIDGE GAP ANALYSIS: There is a substantial gap between biomarker reduction and clinical cardiovascular outcomes. The text explicitly states 'no cardiovascular events were tracked' and outcomes data will not arrive for 4+ years.
4. HEDGE QUALITY CHECK: The company does not hedge its breakthrough claims. Phrases like 'major breakthrough' and 'transform outcomes' are unqualified. The accelerated approval pathway request compounds this by seeking regulatory approval based on surrogate data alone.
5. SURROGATE VALIDITY CAVEAT: While LDL reduction is associated with cardiovascular benefit in observational and some trial data, a 65% reduction in a 12-week Phase 2 trial does not guarantee clinical benefit. Surrogate endpoints can fail (e.g., some antiarrhythmic drugs reduced arrhythmias but increased mortality).
6. MECHANISM VS. EVIDENCE CLASSIFICATION: The text implies human therapeutic benefit (cardiovascular protection, transformed outcomes) based on biomarker evidence without clinical outcome data. This is a classic mechanism-vs-evidence gap: the mechanism (lower LDL → less atherosclerosis → fewer events) is plausible, but the evidence tier (biomarker) does not reach the conclusion tier (clinical benefit).

**Key Claims:**
- The core epistemic problem: LDL reduction (biomarker) is presented as evidence of cardiovascular protection (clinical outcome) without outcome data.
- Accelerated approval based on surrogate endpoints is a regulatory risk if the surrogate does not translate to clinical benefit.
- The 12-week timeframe is too short to assess safety signals that might emerge over years of use.
- The company's language ('breakthrough,' 'transform outcomes') is not hedged despite the absence of clinical outcome data.

**Alternative Hypotheses:**
- Could classify as 'overclaim' if the focus is on the unqualified language ('major breakthrough') rather than the evidence-tier mismatch. However, the core problem is the leap from biomarker to clinical outcome, making mechanism_vs_evidence the primary issue.
- Could classify as 'solid' if one accepts that surrogate endpoints are sufficient for Phase 2 claims and that the company is merely describing what the trial measured. However, the explicit claims about 'cardiovascular protection' and 'transforming outcomes' exceed what a biomarker trial can support.

**Uncertainties:**
- Whether the company's full regulatory submission includes additional data or mechanistic evidence not mentioned in this announcement.
- The specific language used in the accelerated approval request—if it is framed as conditional on future outcomes data, the risk profile changes.
- Whether 'major breakthrough' and 'transform outcomes' are direct quotes from executives or paraphrasing by the announcement author.
- The baseline cardiovascular risk of the trial population and whether the 65% reduction is clinically meaningful in absolute terms (not just relative).

**Self-Verification:**
- Did I correctly identify the evidence tier? Yes—Phase 2 biomarker trial with LDL and safety endpoints is clearly biomarker-tier evidence.
- Did I correctly identify the conclusion tier? Yes—'cardiovascular protection' and 'transform outcomes for patients at high risk of heart attack and stroke' are claims about clinical benefit.
- Is there a bridge gap? Yes—biomarker to clinical outcome is a known gap in drug development.
- Did I overstate the problem? No—the text explicitly states no cardiovascular events were tracked and outcomes data is 4+ years away. This is a genuine evidence-tier mismatch.
- Did I miss a solid aspect? The trial design itself (Phase 2, safety monitoring) appears appropriate for its stage. The problem is not the trial design but the claims made from it.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (0.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 14.4s | 40.0/100 | 2.8 |

Failure modes observed: missed_key_insight, unsupported_conclusion, wrong_answer.
